Biomarin Pharmaceutical (BMRN) EBT (2017 - 2025)
Historic EBT for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to -$26.3 million.
- Biomarin Pharmaceutical's EBT fell 11958.03% to -$26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $679.3 million, marking a year-over-year increase of 7352.67%. This contributed to the annual value of $541.8 million for FY2024, which is 18731.14% up from last year.
- Latest data reveals that Biomarin Pharmaceutical reported EBT of -$26.3 million as of Q3 2025, which was down 11958.03% from $297.9 million recorded in Q2 2025.
- In the past 5 years, Biomarin Pharmaceutical's EBT registered a high of $297.9 million during Q2 2025, and its lowest value of -$66.6 million during Q4 2021.
- In the last 5 years, Biomarin Pharmaceutical's EBT had a median value of $41.7 million in 2023 and averaged $69.2 million.
- As far as peak fluctuations go, Biomarin Pharmaceutical's EBT skyrocketed by 228849.79% in 2023, and later tumbled by 11958.03% in 2025.
- Biomarin Pharmaceutical's EBT (Quarter) stood at -$66.6 million in 2021, then soared by 73.63% to -$17.6 million in 2022, then soared by 210.08% to $19.3 million in 2023, then skyrocketed by 777.73% to $169.6 million in 2024, then tumbled by 115.52% to -$26.3 million in 2025.
- Its EBT stands at -$26.3 million for Q3 2025, versus $297.9 million for Q2 2025 and $238.1 million for Q1 2025.